-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAN-711 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAN-711 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAN-711 in Epilepsy Drug Details: SAN-711 is under development for the treatment of...
-
Product Insights
Epileptic Encephalopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Epileptic Encephalopathy - Drugs In Development, 2023’, provides an overview of the Epileptic Encephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epileptic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Bipolar Disorder (Manic Depression) – Drugs In Development, 2023
Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Drugs In Development, 2023’, provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-880 in Primary Immune Deficiency (PID)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-880 in Primary Immune Deficiency (PID) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-880 in Primary Immune Deficiency (PID) Drug Details: TAK-880 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NN-6434 in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NN-6434 in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NN-6434 in Atherosclerosis Drug Details:NNC-03850434 (NN-6434) is under development for the treatment of familial...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPL-108 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPL-108 in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SPL-108 in Epithelial Ovarian Cancer Drug Details:SPL-108 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSU-6162 in Bipolar I Disorder
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OSU-6162 in Bipolar I Disorder Drug Details: OSU-6162 (PNU-96391) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSU-6162 in Bipolar II Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OSU-6162 in Bipolar II Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OSU-6162 in Bipolar II DisorderDrug Details:OSU-6162 (PNU-96391) is under development for the...